Grace Halsey

500 S TRIMBLE RD

Articles

Vertex on the Verge of Breakthrough for Nonopioid Pain Management as NOPAIN Act Takes Effect

January 13, 2025

Suzetrigine, the investigational selective NaV1.8 pain signal inhibitor, with a PDUFA date of Jan 30, could become a first-in-class nonopioid analgesic.

In Migraine Research, Placebo Effect is Increasingly Reaching Parity with Study Drug Impact: Experts Say, "What?"

January 13, 2025

Migraine expert Peter McAllister, MD, a long-time principal investigator for migraine studies, wonders if study design in this area needs to be re-evaluated.

12 Facts on Wildfire Smoke: Short- and Long-Term Effects on Human Health and the Environment

January 13, 2025

The Los Angeles wildfires continue nearly unabated despite heroic efforts by first responders. Wildfire smoke has both short- and long-term effects on health and habitat. Here's what to know, for you and your patients.

Phase 2b Clinical Trial of Rezpegaldesleukin in Atopic Dermatitis Achieves Target Enrollment

January 13, 2025

Nektar Therapeutics announced the milestone in its clinical program to evaluate the IL-2 receptor agonist, a potential first-in-class treatment for the chronic condition.

Atumelnant Demonstrates Rapid and Sustained Biomarker Reduction in Phase 2 Trial in Adults with Congenital Adrenal Hyperplasia

January 10, 2025

Atumelnant treatment resulted in statistically significant reductions in serum androstenedione and 17-OHP as well as notable improvements in CAH symptoms.

American Headache Society Statement on CGRP Inhibitors is Driving Significant Change: Neurologist Peter McAllister, MD

January 10, 2025

"This AHS statement has exceeded our wildest dreams..." McAllister said of the impact of the society recommendation that CGRP inhibitors be considered among first-line treatment for migraine.

Inmagene Announces Favorable Topline Efficacy and Safety Results for IMG-007 in Atopic Dermatitis

January 10, 2025

Intravenous IMG-007 at study weeks 0, 2, and 4 led to a mean reduction in EASI of 77% as early as week 4; more than half of participants reached EASI-75 at week 16.

Elinzanetant Meets All Endpoints in Phase 3 Study of VMS Caused by Adjuvant Endocrine Therapy for Breast Cancer

January 09, 2025

Elinzanetant produced a statistically significant reduction in frequency of treatment-related vasomotor symptoms as early as week 1 and in severity at weeks 4 and 12.

New Guidelines on Diagnosing Alzheimer’s Disease and Related Cognitive Impairments: A Comprehensive Framework for Primary Care

January 09, 2025

The first US interdisciplinary evaluation guideline will help primary care clinicians address the rising prevalence of AD and ADRD seen in their front-line clinical setting.

FDA Proposes Sustained 5% Weight Loss to Establish Efficacy of New Antiobesity Medications

January 08, 2025

In an unusual step, the agency's draft guidance recommends the efficacy benchmark for drug approval while emphasizing clinical trial structure and cohort development.